Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

xvivo perfusion - XVIPY

XVIPY

Close Chg Chg %
6.54 -0.20 -3.06%

Closed Market

6.34

-0.20 (3.06%)

Volume: 152.00

Last Updated:

Feb 4, 2026, 9:30 AM EDT

Trade Now

Company Overview: xvivo perfusion - XVIPY

XVIPY Key Data

Open

$6.34

 Day Range

6.34 - 6.34

52 Week Range

4.25 - 10.81

 Market Cap

$721.97M

Shares Outstanding

126.00M

 Public Float

N/A

Beta

1.85

 Rev. Per Employee

N/A

P/E Ratio

293.28

 EPS

$0.02

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

  

XVIPY Performance

1 Week
 
 -3.06%
 
1 Month
 
 37.83%
 
3 Months
 
 -25.24%
 
1 Year
 
 N/A
 
5 Years
 
 N/A
 

XVIPY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Xvivo Perfusion - XVIPY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
41.04M 56.29M 77.79M 82.81M
Sales Growth
+36.34% +37.16% +38.20% +6.46%
Cost of Goods Sold (COGS) incl D&A
13.05M 17.01M 25.68M 28.41M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.56M 2.91M 6.38M 7.16M
Depreciation
1.41M 2.19M 3.07M 4.01M
Amortization of Intangibles
148.91K 716.94K 3.31M 3.15M
COGS Growth
+10.40% +30.43% +50.91% +10.66%
Gross Income
27.99M 39.27M 52.11M 54.40M
Gross Income Growth
+53.11% +40.30% +32.69% +4.39%
Gross Profit Margin
+68.21% +69.77% +66.99% +65.69%
2022 2023 2024 2025 5-year trend
SG&A Expense
26.16M 35.65M 41.18M 44.91M
Research & Development
6.39M 12.18M 10.68M 10.27M
Other SG&A
19.77M 23.47M 30.50M 34.65M
SGA Growth
+39.24% +36.23% +15.52% +9.07%
Other Operating Expense
- - - -
-
Unusual Expense
1.41M 3.63M 2.58M 820.19K
EBIT after Unusual Expense
418.58K (3.39K) 8.35M 8.66M
Non Operating Income/Expense
1.89M 9.02M 11.09M (208.41K)
Non-Operating Interest Income
- 209.78K 833.65K 1.62M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
108.10K 112.10K 529.76K 4.52M
Interest Expense Growth
+236.25% +3.69% +372.60% +753.95%
Gross Interest Expense
108.10K 112.10K 529.76K 4.52M
Interest Capitalized
- - - -
-
Pretax Income
2.20M 8.90M 18.91M 3.93M
Pretax Income Growth
+184.00% +303.80% +112.40% -79.21%
Pretax Margin
+5.37% +15.82% +24.31% +4.75%
Income Tax
384.09K 254.43K 2.63M 1.37M
Income Tax - Current - Domestic
- 90.42K 1.36M 778.32K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- 293.68K (1.10M) 1.85M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.82M 8.65M 16.29M 2.57M
Minority Interest Expense
- - - -
-
Net Income
1.82M 8.65M 16.29M 2.57M
Net Income Growth
+91.75% +375.01% +88.29% -84.25%
Net Margin Growth
+4.44% +15.37% +20.94% +3.10%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.82M 8.65M 16.29M 2.57M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.82M 8.65M 16.29M 2.57M
EPS (Basic)
0.0154 0.0722 0.1293 0.0204
EPS (Basic) Growth
+87.80% +368.83% +79.09% -84.22%
Basic Shares Outstanding
118.10M 119.74M 126.00M 126.00M
EPS (Diluted)
0.0154 0.0722 0.1286 0.0203
EPS (Diluted) Growth
+87.80% +368.83% +78.12% -84.21%
Diluted Shares Outstanding
118.10M 119.74M 126.60M 126.23M
EBITDA
3.39M 6.53M 17.31M 16.64M
EBITDA Growth
+4.31% +92.86% +164.92% -3.86%
EBITDA Margin
+8.26% +11.61% +22.25% +20.10%

Xvivo Perfusion in the News